Laura Hamill
CIK 1751804 · EVP, Worldwide Commercial Ops · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.50M
Companies
8
Total Filings
28
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 8,538 | $256.56 | $2.19M | $0 | 3 | 2026-08-07 |
| FATE | Director | — | $2.80 | — | $0 | 1 | 2026-06-15 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 30,905 | $8.61 | $266.1K | $0 | 6 | 2025-07-02 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | Director | — | $2.16 | — | $0 | 4 | 2023-08-31 |
| SCLXW | Director | — | $0.21 | — | $0 | 1 | 2023-01-17 |
| ANAB | Director | — | $56.61 | — | $0 | 5 | 2023-01-10 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | $0 | 3 | 2021-11-22 |
| GILD | EVP, Worldwide Commercial Ops | 9,840 | $133.21 | $1.31M | $0 | 3 | 2019-05-10 |
Recent Filings · Page 3 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-02 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +474 | $0 | EDGAR |
| 2020-09-17 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-24 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-13 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2019-09-26 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2019-05-10 | GILD | Mixed | +6,340 | -$231.2K | EDGAR |
| 2019-02-08 | GILD | Grant (A) | — | $0 | EDGAR |
| 2018-10-09 | GILD | Grant (A) | — | $0 | EDGAR |
Showing 21–28 of 28
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.